Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

GlaxoSmithKline51 enrolled

Overview

The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of inhaled GSK573719 and GW64244 compared to placebo, in subjects with COPD.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of the combination of GSK573719 (500mcg) Inhalation Powder and GW642444 (25mcg) Inhalation Powder administered once-daily via a novel dry powder inhaler (Novel DPI) over 28 days in subjects with COPD

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

500mcg/25mcg once dailyDRUG

GSK573719/GW642444

Placebo once dailyDRUG

Inactive, excipients only

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A signed and dated written informed consent prior to study participation * Males or females of non-childbearing potential * 40 or more years of age * COPD diagnosis * 10 pack-years history or greater of cigarette smoking * Post-bronchodilator FEV1/FVC ratio of 0.70 or less * Post-bronchodilator FEV1 of 80% or less of predicted normal Exclusion Criteria: * Current diagnosis of asthma * Other significant respiratory disorders besides COPD, including alpha-1 deficiency * Previous lung resection surgery * Significant abnormalities in chest x-ray presentation * Use of oral steroids, antibiotics or hospitalization for a COPD exacerbation within 3 motnhs prior screening * Any significant disease that would put subject at risk through study participation * BMI greater than 35 * Pacemaker * Significantly abnormal ECG, Holter, or clinical lab finding (including Hepatitis B or C) * Cancer * Allergy or hypersensitivity to anticholinergics or inhaler excipients * Diseases that would contra-indicate the use of anticholinergics * Use of oral corticosteroids within 6 weeks of screening * Use of long-acting beta-agonists within 48 hours of screening * Use of tiotropium within 14 days of screening * Use of theophyllines or anti-leukotrienes within 48 hours of screening * Use of short-acting bronchodilators within 4 hours of screening * Use of investigational medicines within 30 days of screening * Use of high dose inhaled corticosteroids * Use of long-term oxygen therapy, CPAP or NIPPV * Previous use of GSK573719 or GW642444

Locations (4)

GSK Investigational Site

Chester, South Carolina, United States

GSK Investigational Site

Gaffney, South Carolina, United States

GSK Investigational Site

Greenville, South Carolina, United States

GSK Investigational Site

Greenwood, South Carolina, United States

Outcomes

Primary Outcomes

Change From Baseline in Weighted Mean Pulse Rate Over 0 to 6 Hours Post-dose at Day 28

Pulse rate is defined as the number of heartbeats in a minute. The weighted mean pulse rate was derived by calculating the area under the pulse rate/time curve (AUC), and then dividing the value by the time interval over which the AUC was calculated. The weighted mean pulse rate was calculated using the 0 to 6 hours post dose measurements at Day 28, which included pre-dose, and post-dose 15 minutes, 45 minutes, 1.5 hours, 3 hours and 6 hours. Baseline pulse rate is the most recent result taken on or before pre-dose Day 1. Change from Baseline is the weighted mean pulse rate at Day 28 minus the Baseline value. Analysis was performed using a repeated measures model with covariates of Baseline pulse rate, sex, age, smoking status, treatment and day and day by treatment and day by Baseline interactions.

Time frame: Baseline and Day 28

Secondary Outcomes

Change From Baseline in Weighted Mean Pulse Rate Over 0 to 6 Hours Post-dose at Day 1 and Day 14

Pulse rate is defined as the number of heartbeats in a minute. The weighted mean pulse rate was derived by calculating the area under the pulse rate/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The weighted mean pulse rate was calculated using the 0 to 6 hours post dose measurements on Day 1 and Day 14, which included pre-dose, and post-dose 15 minutes, 45 minutes, 1.5 hours, 3 hours and 6 hours. Baseline pulse rate is the most recent result taken on or before pre-dose Day 1. Change from Baseline is the weighted mean pulse rate at Day 1 or Day 14 minus the Baseline value. Analysis was performed using a repeated measures model with covariates of Baseline pulse rate, sex, age, smoking status, treatment and day and day by treatment and day by Baseline interactions.

Time frame: Baseline, Day 1, and Day 14

Change From Baseline in Maximum and Minimum Pulse Rate 0 to 6 Hours Post-dose on Days 1, 14, and 28

Pulse rate is defined as the number of heartbeats in a minute (m). A maximum post-Baseline pulse rate was derived as the maximum value recorded at Days 1, 14 and 28. A minimum post-Baseline pulse rate was derived as the minimum value recorded at Days 1, 14 and 28. The maximum and minimum pulse rates were calculated using the 0 to 6 hours (h) post dose measurements on Days 1, 14 and 28, which included pre-dose, and post-dose 15 m, 45 m, 1.5 h, 3 h and 6 h. Maximum and minimum post-Baseline rate were calculated using the nominal 0-6 h post-dose records, and only records collected during the actual 0-7 h post-dose interval were used. Baseline pulse rate is the most recent result taken on or before pre-dose Day 1. Change from Baseline is the maximum or minimum pulse rate minus the Baseline value. Analysis performed using a repeated measures model with covariates of Baseline pulse rate, sex, age, smoking status, treatment and day and day by treatment and day by Baseline interactions.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.